[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"condbio:solid-neoplasm:pik3ca-gene":3},{"condition":4,"biomarker":5,"total":6,"trials":7},"Solid Neoplasm","PIK3CA Gene",9,[8,16,23,29,35,41,47,53,59],{"nct_id":9,"title":10,"phases":11,"status":13,"updated_at":14,"content_modified":15},"NCT03424005","A Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Patients With Metastatic or Locally Advanced Breast Cancer",[12],"Phase 1\u002FPhase 2","RECRUITING","2026-08-26T02:15:26.669629Z","2026-06-17T19:21:16.689089Z",{"nct_id":17,"title":18,"phases":19,"status":13,"updated_at":21,"content_modified":22},"NCT05216432","First-in-Human Study of Mutant-selective PI3Kα Inhibitor, RLY-2608, as a Single Agent in Patients With Advanced Solid Tumors and in Combination With Endocrine Therapy +\u002F- a CDK4\u002F6 or CDK4 Inhibitor in Patients With Advanced Solid Tumors or Advanced Breast Cancer",[20],"Phase 1","2026-08-26T02:19:26.493949Z","2026-05-05T02:43:27.492318Z",{"nct_id":24,"title":25,"phases":26,"status":13,"updated_at":27,"content_modified":28},"NCT06736704","SNV4818 in Participants With Advanced Solid Tumors",[12],"2026-08-26T02:19:05.360997Z","2026-04-29T02:57:57.076319Z",{"nct_id":30,"title":31,"phases":32,"status":13,"updated_at":33,"content_modified":34},"NCT07383506","A Study of Mutant Selective-Inhibitor (CGT6297), in Patients With Advanced Solid Tumors",[20],"2026-08-26T02:18:14.396999Z","2026-05-05T02:43:29.192289Z",{"nct_id":36,"title":37,"phases":38,"status":13,"updated_at":39,"content_modified":40},"NCT06625775","Open-Label Study of BBO-10203 in Subjects With Advanced Solid Tumors",[20],"2026-08-26T02:17:09.131534Z","2026-05-05T02:43:28.969601Z",{"nct_id":42,"title":43,"phases":44,"status":13,"updated_at":45,"content_modified":46},"NCT07524322","Study of RGT-490 in Patients With PIK3CA-Mutated Advanced Solid Tumors",[20],"2026-08-26T02:16:01.079019Z","2026-05-05T02:43:28.715467Z",{"nct_id":48,"title":49,"phases":50,"status":13,"updated_at":51,"content_modified":52},"NCT06993844","Phase 1\u002F2 Study of ETX-636 in Participants With Advanced Solid Tumors",[12],"2026-08-26T02:17:23.750999Z","2026-05-05T02:43:27.756864Z",{"nct_id":54,"title":55,"phases":56,"status":13,"updated_at":57,"content_modified":58},"NCT05039801","IACS-6274 With or Without Bevacizumab and Paclitaxel for the Treatment of Advanced Solid Tumors",[20],"2026-08-26T02:18:49.989941Z","2026-04-29T02:57:57.070174Z",{"nct_id":60,"title":61,"phases":62,"status":13,"updated_at":63,"content_modified":64},"NCT05307705","A Study of LOXO-783 in Patients With Breast Cancer\u002FOther Solid Tumors",[20],"2026-08-26T02:16:00.194860Z","2026-07-24T01:27:14.903653Z"]